Product Information
MEXILETINE 150 MG CAPSULE is a generic product labeled by Sun Pharmaceutical Industries Inc., priced at $0.2225 per EA under NDC 62756095501. Its NADAC has been published 237 times since Mar 23, 2022.
FDA first approved this application on Oct 1, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Sun Pharmaceutical Industries Inc.NDC
62756095501
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MEXILETINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA214089FDA Approved
10/1/2021
TE Code
AB
On Market Since
11/29/2021
Pharmacological Classes
Price Statistics
The NADAC for MEXILETINE 150 MG CAPSULE has been published 237 times since Mar 23, 2022, and over the history we have for it it has declined 70.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2225 per EA |
|---|---|
| All-time high | $0.7627 (Apr 13, 2022) |
| All-time low | $0.2193 (Jul 17, 2024) |
| 52-week high | $0.2591 |
| 52-week low | $0.2225 |
| Median price | $0.2994 |
| Average price | $0.3531 |
| Largest weekly change | -34.2% (Apr 17, 2024) |
| Weeks tracked | 237 |
| Tracking since | Mar 23, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the mexiletine hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sun Pharmaceutical Industries Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
mexiletine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antiarrhythmic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MEXILETINE 150 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for MEXILETINE 150 MG CAPSULE, manufactured by Sun Pharmaceutical Industries Inc., is $0.2225 per EA (NDC 62756095501), effective Sep 30, 2026.
How has the price of MEXILETINE 150 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for MEXILETINE 150 MG CAPSULE has declined 70.8%. It has been tracked across 237 weekly CMS publications since Mar 23, 2022.
What are the highest and lowest recorded NADAC prices for MEXILETINE 150 MG CAPSULE?
Since Mar 23, 2022, the NADAC for MEXILETINE 150 MG CAPSULE has ranged from a low of $0.2193 (Jul 17, 2024) to a high of $0.7627 (Apr 13, 2022), with a median of $0.2994 per EA.
Are there cheaper alternatives to MEXILETINE 150 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of MEXILETINE 150 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures MEXILETINE 150 MG CAPSULE?
MEXILETINE 150 MG CAPSULE (NDC 62756095501) is labeled by Sun Pharmaceutical Industries Inc., and CMS classifies it as a generic product.